Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar

References

• Friese MA, Schattling B, Fugger L. Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 2014;10:225-38
   PubMed Web of Science ®Google Scholar
• Farber RS, Sand IK. Optimizing the initial choice and timing of therapy in relapsing–remitting multiple sclerosis. Ther Adv Neurol Disord 2015;8:212-32
   PubMed Web of Science ®Google Scholar
• Heydarpour P, Khoshkish S, Abtahi S, et al. Multiple sclerosis epidemiology in Middle East and North Africa: a systematic review and meta-analysis. Neuroepidemiology 2015;44:232-44
   PubMed Web of Science ®Google Scholar
• Benamer HTS, Ahmed ESM, Al Din AS, et al. Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review. J Neurol Sci 2009;278:1-4
   PubMed Web of Science ®Google Scholar
• Alroughani R, Ahmed SF, Behbahani R, et al. Increasing prevalence and incidence rates of multiple sclerosis in Kuwait. Mult Scler 2014;20:543-7
   PubMed Web of Science ®Google Scholar
• Deleu D, Mir D, Al Tabouki A, et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler 2013;19:816-19
   PubMed Web of Science ®Google Scholar
• Inshasi J, Thakre M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int J Neurosci 2011;121:393-8
   PubMed Web of Science ®Google Scholar
• Alshubaili AF, Alramzy K, Ayyad YM, et al. Epidemiology of multiple sclerosis in Kuwait: new trends in incidence and prevalence. Eur Neurol 2005;53:125-31
   PubMed Web of Science ®Google Scholar
• Ebers G. Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268-77
   PubMed Web of Science ®Google Scholar
• Al Jumah M, Kojan S, Al Khathaami A, et al. Familial multiple sclerosis: does consanguinity have a role? Mult Scler 2011;17:487-9
   PubMed Web of Science ®Google Scholar
• Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8
   PubMed Web of Science ®Google Scholar
• Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132:1146-60
   PubMed Web of Science ®Google Scholar
• Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-32
   PubMed Web of Science ®Google Scholar
• Smolders J, Menheere P, Kessels A, et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008;14:1220-4
   PubMed Web of Science ®Google Scholar
• Muris AH, Rolf L, Broen K, et al. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. J Steroid Biochem Mol Biol 2015
   PubMed Web of Science ®Google Scholar
• Badawi A, Arora P, Sadoun E, et al. Prevalence of vitamin D insufficiency in Qatar: a systematic review. J Public Health Res 2012;1:229-35
   PubMedGoogle Scholar
• Giovannoni G, Turner B, Gnanapavan S, et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 2015;4:329-33
   PubMed Web of Science ®Google Scholar
• Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing–Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-60
   PubMed Web of Science ®Google Scholar
• Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of “no evidence of disease activity” (NEDA-4) in relapsing–remitting multiple sclerosis. Mult Scler 2016:22;1297-305
   PubMed Web of Science ®Google Scholar
• Aliaga ES, Barkhof F. MRI mimics of multiple sclerosis. Handb Clin Neurol 2014;122:291-316
   PubMedGoogle Scholar
• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278-86
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-46
   Google Scholar
• Okuda DT, Mowry EM, Cree BA, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology 2011;76:686-92
   PubMed Web of Science ®Google Scholar
• Giorgio A, Stromillo ML, Rossi F, et al. Cortical lesions in radiologically isolated syndrome. Neurology 2011;77:1896-9
   PubMed Web of Science ®Google Scholar
• Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012;11:157-69
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
   PubMed Web of Science ®Google Scholar
• Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler 2010;16:156-65
   PubMed Web of Science ®Google Scholar
• Kinkel RP, Dontchev M, Kollman C, et al. Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: a 10-year follow-up of the Controlled High-Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Arch Neurol 2012;69:183-90
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
   PubMed Web of Science ®Google Scholar
• Kinkel RP, Kollman C, O’Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-84
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 2013;19:1074-83
   PubMed Web of Science ®Google Scholar
• Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol 2005;11:379-89
   Web of Science ®Google Scholar
• Dubey D, Cano CA, Stuve O. Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab. Neuropsychiatr Dis Treat 2015;11:2405-14
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29
   PubMed Web of Science ®Google Scholar
• Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17
   PubMed Web of Science ®Google Scholar
• Sormani MP, De Stefano N. Defining and scoring response to IFN-β in multiple sclerosis. Nature Rev Neurol 2013;9:504-12
   PubMed Web of Science ®Google Scholar
• Freedman MS, Cohen B, Dhib-Jalbut S, et al. Recognizing and treating suboptimally controlled multiple sclerosis: steps toward regaining command. Curr Med Res Opin 2009;25:2459-70
   PubMed Web of Science ®Google Scholar
• Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon β. Ann Neurol 2013;73:95-103
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010;74(Suppl 1):S17-S24
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Paty DW, Li DK. Interferon beta-1b is effective in relapsing–remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Rice GP, Incorvaia B, Munari L, et al. Interferon in relapsing–remitting multiple sclerosis. Cochrane Database Syst Rev 2001;4:CD002002
   Google Scholar
• Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta1a in secondary progressive MS. Clinical results. Neurology 2001;56:1496-504
   PubMed Web of Science ®Google Scholar
• Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon b-1a on MSFC progression in secondary progressive MS. Neurology 2002;59:679-87
   PubMed Web of Science ®Google Scholar
• Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-95
   PubMed Web of Science ®Google Scholar
• Leary SM, Miller DH, Stevenson VL, et al. Interferon b-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44-51
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Early Treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. CHAMPS Study Group. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing–remitting MS. Neurology 2006;67:944-53
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11:33-41
   PubMed Web of Science ®Google Scholar
• Clerico M, Faggiano F, Palace J, et al. Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008;2:CD005278
   Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97
   PubMed Web of Science ®Google Scholar
• Edan G, Kappos L, Montalbán X, et al. Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. J Neurol Neurosurg Psychiatry 2014;85:1183-9
   PubMed Web of Science ®Google Scholar
• Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing remitting multiple sclerosis. JAMA 2012;308:247-56
   PubMed Web of Science ®Google Scholar
• Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12
   PubMed Web of Science ®Google Scholar
• Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther 2003;25:105-18
   PubMed Web of Science ®Google Scholar
• Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
   PubMed Web of Science ®Google Scholar
• Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose–Response–European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29:2031-48
   PubMed Web of Science ®Google Scholar
• Calabresi P, Kieseier B, Arnold D, et al. Pegylated interferon β-1a for relapsing–remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 2014;13:657-65
   PubMed Web of Science ®Google Scholar
• Kieseier B, Arnold D, Balcer L, et al. Peginterferon β-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler 2014;21:1025-35
   PubMed Web of Science ®Google Scholar
• Dubey D, Cano CA, Stüve O. Update on monitoring and adverse effects of first generation disease modifying therapies and their recently approved versions in relapsing forms of multiple sclerosis. Curr Opin Neurol 2016;29:272-7
   PubMed Web of Science ®Google Scholar
• Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, openlabel trial. Lancet Neurol 2008;7:903-14
   PubMed Web of Science ®Google Scholar
• O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing–remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012;18:932-46
   PubMed Web of Science ®Google Scholar
• Hegen H, Schleiser M, Gneiss C, et al. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation. Mult Scler 2012;18:610-15
   PubMed Web of Science ®Google Scholar
• Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740-50
   PubMed Web of Science ®Google Scholar
• Jungedal R, Lundkvist M, Engdahl E, et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012;18:1775-81
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74
   PubMed Web of Science ®Google Scholar
• Barbero P, Bergui M, Versino E, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb. Mult Scler 2006;12:72-6
   PubMed Web of Science ®Google Scholar
• Hartung HP, Freedman MS, Polman CH, et al. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011;77:835-43
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Alteri E, Moraga MS, et al. Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler 2011;17:423-30
   PubMed Web of Science ®Google Scholar
• Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79:1130-5
   PubMed Web of Science ®Google Scholar
• Thiel S, Langer-Gould A, Rockhoff M, et al. Interferon-beta exposure during first trimester is safe in women with multiple sclerosis – a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry. Mult Scler 2016;22:801-9
   PubMed Web of Science ®Google Scholar
• Ellerman K, Brostoff S. A suppressor cell line that prevents the adoptive transfer of EAE in Lewis rats. Ann N Y Acad Sci 1988;540:364-6
   PubMedGoogle Scholar
• Racke MK, Lovett-Racke AE. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J Immunol 2011;186:1887-90
   PubMed Web of Science ®Google Scholar
• Skihar V, Silva C, Chojnacki A, et al. Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci USA 2009;106:17992-7
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol 2013;73:705-13
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-7
   PubMed Web of Science ®Google Scholar
• Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating remitting multiple sclerosis. N Engl J Med 1987;317:408-14
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler 2003;9:349-55
   PubMed Web of Science ®Google Scholar
• La Mantia L, Munari LM, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst Rev 2010;5:CD004678
   Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo controlled trial. Lancet 2009;374:1503-11
   PubMed Web of Science ®Google Scholar
• Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFN beta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009;72:1976-83
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327-40
   PubMed Web of Science ®Google Scholar
• Teitelbaum D, Webb C, Bree M, et al. Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 1974;3:256-62
   PubMedGoogle Scholar
• Lu E, Wang BW, Guimond C, et al. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79:1130-5
   PubMed Web of Science ®Google Scholar
• Giannini M, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. BMC Neurol 2012;12:124
   PubMed Web of Science ®Google Scholar
• Fragoso YD. Glatiramer acetate to treat multiple sclerosis during pregnancy and lactation: a safety evaluation. Expert Opin Drug Saf 2014;13:1743-8
   PubMed Web of Science ®Google Scholar
• Osiri M, Shea B, Robinson V, et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003;1:CD002047
   Google Scholar
• Bruneau JM, Yea CM, Spinella-Jaegle S, et al. Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide. Biochem J 1998;336(Pt 2):299-303
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Pachner A, Menguy-Vacheron F, et al. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014;74:659-74
   PubMed Web of Science ®Google Scholar
• O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303
   PubMed Web of Science ®Google Scholar
• Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56
   PubMed Web of Science ®Google Scholar
• Vermersch P, Czlonkowska A, Grimaldi LM, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16
   PubMed Web of Science ®Google Scholar
• Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:977-86
   PubMed Web of Science ®Google Scholar
• Chan A, de Seze J, Comabella M. Teriflunomide in patients with relapsing–remitting forms of multiple sclerosis. CNS Drugs 2016;30:41-51
   PubMed Web of Science ®Google Scholar
• O’Connor P, Comi G, Freedman MS, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology 2016;86:920-30
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing–remitting multiple sclerosis. Neurol Ther 2014;3:133-8
   PubMedGoogle Scholar
• Papadopoulou A, Kappos L, Sprenger T. Safety of teriflunomide for the management of relapsing–remitting multiple sclerosis. Expert Opin Drug Saf 2015;14:749-59
   PubMed Web of Science ®Google Scholar
• di Nuzzo L, Orlando R, Nasca C, et al. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug Des Devel Ther 2014;8:555-68
   PubMed Web of Science ®Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Arnold DL, Gold R, Kappos L, et al. Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 DEFINE study. J Neurol 2014;261:1794-802
   PubMed Web of Science ®Google Scholar
• Gold R, Arnold DL, Bar-Or A, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler 2016: published online 19 May 2016
   Google Scholar
• O’Gorman J, Russell HK, Li J, et al. Effect of aspirin pretreatment or slow dose titration on flushing and gastrointestinal events in healthy volunteers receiving delayed-release dimethyl fumarate. Clin Ther 2015;37:1402-19
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Naismith RT, Parks BJ, et al. Dimethyl fumarate-associated lymphopenia: risk factors and clinical significance. Mult Scler J Exp Transl Clin 2015;1
   PubMedGoogle Scholar
• EMA recommendation: updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2015/10/news_detail_002423.jsp&mid=WC0b01ac058004d5c1 [Last accessed 3 June 2016]
   Google Scholar
• Gold R, Phillips JT, Havrdova E, et al. Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience. Neurol Ther 2015;4:93-104
   PubMed Web of Science ®Google Scholar
• Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol 2009;158:1173-82
   PubMed Web of Science ®Google Scholar
• Ingwersen J, Aktas O, Kuery P, et al. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy. Clin Immunol 2012;142:15-24
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:40215
   Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013;260:2023-32
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Schwarz HJ, Fuchs A, et al. 36 month PANGAEA: A 5-year non-interventional study of safety, efficacy and pharmacoeconomic data for fingolimod patients in daily clinical practice. Neurology 2015;84(Suppl):P3.251
   PubMed Web of Science ®Google Scholar
• Novartis Pharma GmbH. Gilenya SmPC. September 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf [Last accessed February 2015]
   Google Scholar
• Zarbin MA, Jampol LM, Jager RD, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology 2013;120:1432-9
   PubMed Web of Science ®Google Scholar
• Available at: https://www.gov.uk/drug-safety-update/fingolimod-gilenya-risks-of-progressive-multifocal-leukoencephalopathy-basal-cell-carcinoma-and-opportunistic-infections [Last accessed 3 June 2016]
   Google Scholar
• https://www.novartis.com/sites/www.novartis.com/files/q4-2015-ir-presentation.pdf
   Google Scholar
• Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology 2014;82:674-80
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005;64:1336-42
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol 2009;256:405-15
   PubMed Web of Science ®Google Scholar
• Barbin L, Rousseau C, Jousset N, et al. Comparative efficacy of fingolimod vs natalizumab: a French multicenter observational study. Neurology 2016;86:771-8
   PubMed Web of Science ®Google Scholar
• Wilken J, Kane R, Sullivan C, et al. Changes in fatigue and cognition in patients with relapsing forms of multiple sclerosis treated with natalizumab: the ENER-G Study. Int J MS Care 2013;15:120-8
   PubMedGoogle Scholar
• Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
   PubMed Web of Science ®Google Scholar
• McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry 2016;87:117-25
   PubMed Web of Science ®Google Scholar
• Biogen MedInfo. Available at: https://medinfo.biogen.com [Last accessed 1 April 2016]
   Google Scholar
• Tan IL, McArthur JC, Clifford DB, et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 2011;77:1061-7
   PubMed Web of Science ®Google Scholar
• Sørensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014;261:1170-7
   PubMed Web of Science ®Google Scholar
• Ferrè L, Moiola L, Sangalli F, et al. Recurrence of disease activity after repeated natalizumab withdrawals. Neurol Sci 2015;36:465-7
   PubMed Web of Science ®Google Scholar
• Lo Re M, Capobianco M, Ragonese P, et al. Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers. Neurol Ther 2015;4:147-57
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, Comi G, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology 2015;85:29-39
   PubMed Web of Science ®Google Scholar
• Vennegoor A, Rispens T, Strijbis EM, et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013;19:593-600
   PubMed Web of Science ®Google Scholar
• Ebrahimi N, Herbstritt S, Gold R, et al. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015;21:198-205
   PubMed Web of Science ®Google Scholar
• Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014;71:891-5
   PubMed Web of Science ®Google Scholar
• Ruck T, Bittner S, Wiendl H, et al. alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 2015;16:16414-39
   PubMed Web of Science ®Google Scholar
• Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing–remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28
   PubMed Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• Caon C, Namey M, Meyer C, et al. Prevention and management of infusion-associated reactions in the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) Program. Int J MS Care 2015;17:191-8
   PubMedGoogle Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015;86:208-15
   PubMed Web of Science ®Google Scholar
• Genzyme Therapeutics Ltd. Lemtrada SmPC. March 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf [Last accessed June 2016]
   Google Scholar
• Oh J, Achiron A, Chambers C, et al. Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program. Neurology 2016;86(16 Suppl):S24.008
   Google Scholar
• Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013;10:55-67
   PubMed Web of Science ®Google Scholar
• Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing–remitting multiple sclerosis (SELECT): a randomized, double-blind, placebo-controlled trial. Lancet 2013;381:2167-75
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Radue EW, Havrdova E, et al. Effect of daclizumab high-yield process in patients with highly active relapsing–remitting multiple sclerosis. J Neurol 2014;261:316-23
   PubMed Web of Science ®Google Scholar
• Kappos L, Wiendl H, Selmaj K, et al. Daclizumab HYP versus interferon beta 1a in relapsing multiple sclerosis. N Engl J Med 2015;373:1418-28
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Gold R, Selmaj K, et al. Daclizumab high-yield process in relapsing–remitting multiple sclerosis (SELECTION): a multicentre, randomized, double-blind extension trial. Lancet Neurol 2014;13:472-81
   PubMed Web of Science ®Google Scholar
• Radue EW, Giovannoni G, Gold R, et al. Long-term efficacy of daclizumab HYP in relapsing–remitting multiple sclerosis: 3 year results from the SELECTED Extension Study. Neurology 2015;84(Suppl 14):P7.226
   Google Scholar
• Giovannoni G, Kappos L, Gold R, et al. Safety and tolerability profile of daclizumab in patients with relapsing–remitting multiple sclerosis: an integrated analysis of clinical studies. Mult Scler Relat Disord 2016;9:36-46
   PubMed Web of Science ®Google Scholar
• Gold R, Stefoski D, Selmaj K, et al. Pregnancy experience: nonclinical studies and pregnancy outcomes in the daclizumab clinical study program. Neurol Ther 2016: published online 13 July 2016, doi: 10.1007/s40120-016-0048-2
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, et al.; HERMES Trial Group. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med 2008;358:676-88
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol 2010;67:452-61
   PubMed Web of Science ®Google Scholar
• Hauser S, Arnold S, Bar-Or A, et al. Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies. Neurology 2016;86(Suppl 49):S49.003
   Google Scholar
• Available at: http://www.roche.com/irp151012.pdf
   Google Scholar
• Fox EJ. Mechanism of action of mitoxantrone. Neurology 2004;63(12 Suppl 6):S15-S18
   PubMed Web of Science ®Google Scholar
• Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing–remitting multiple sclerosis: 24 month clinical and MRI outcome. J Neurol 1997;244:153-9
   PubMed Web of Science ®Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2013;5:CD002127
   PubMedGoogle Scholar
• Marriott JJ, Miyasaki JM, Gronseth G, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-70
   PubMed Web of Science ®Google Scholar
• Rivera VM, Jeffery DR, Weinstock-Guttman B, et al. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013;13:80
   PubMed Web of Science ®Google Scholar
• Le Page E, Leray E, Edan G.; French Mitoxantrone Safety Group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17:867-75
   PubMed Web of Science ®Google Scholar
• Kingwell E, Koch M, Leung B, et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS. Neurology 2010;74:1822-6
   PubMed Web of Science ®Google Scholar
• Buttmann M, Seuffert L, Mäder U, et al. Malignancies after mitoxantrone for multiple sclerosis: a retrospective cohort study. Neurology 2016;86:2203-7
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010;133:1914-29
   PubMed Web of Science ®Google Scholar
• Gajofatto A, Bacchetti P, Grimes B, et al. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing–remitting multiple sclerosis. Mult Scler 2009;15:50-8
   PubMed Web of Science ®Google Scholar
• Prosperini L, Giannì C, Leonardi L, et al. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Mult Scler 2012;18:64-71
   PubMed Web of Science ®Google Scholar
• Carrá A, Onaha P, Luetic G, et al. Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing–remitting multiple sclerosis in Argentina. Eur J Neurol 2008;15:386-93
   PubMed Web of Science ®Google Scholar
• Edan G, Comi G, Le Page E, et al. French Italian Mitoxantrone Interferon-beta-1b Trial Group. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011;82:1344-50
   PubMed Web of Science ®Google Scholar
• Vollmer T, Panitch H, Bar-Or A, et al. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler 2008;14:663-70
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304
   PubMed Web of Science ®Google Scholar
• Yamout B, Alroughani R, Al-Jumah M, et al. Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Curr Med Res Opin 2013;29:611-21
   PubMed Web of Science ®Google Scholar
• Yamout B, Alroughani R, Al-Jumah M, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin 2015;31:1349-61
   PubMed Web of Science ®Google Scholar
• Alroughani R, Ashkanani A, Al-Hashel J, et al. Consensus recommendations for the diagnosis and treatment of multiple sclerosis in Kuwait. Clin Neurol Neurosurg 2016;143:51-64
   PubMed Web of Science ®Google Scholar
• Freedman MS, Selchen D, Arnold DL, et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40:307-23
   PubMed Web of Science ®Google Scholar
• Freedman MS, Forrestal FG. Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon beta-1a: analysis of the PRISMS study. Mult Scler 2008;14:1234-41
   PubMed Web of Science ®Google Scholar